Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2011

01-08-2011 | Original Paper

Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays

Authors: Georg Sauer, Nicole Schneiderhan-Marra, Rainer Muche, Karin Koretz, Cornelia Kazmaier, Rolf Kreienberg, Thomas Joos, Helmut Deissler

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2011

Login to get access

Abstract

Purpose

Purpose of this study was to determine the accuracy of prediction of non-sentinel lymph node (NSLN) involvement in sentinel node (SLN)-positive breast cancer patients based on protein concentrations measured in lysates from initially taken breast biopsies.

Methods

Data on protein expression, previously generated by multiplexed bead-based immunoassays, were analysed by multivariate logistic regression to define parameter sets of value to predict NSLN involvement. Receiver-operator characteristics (ROCs) were calculated as indicators of diagnostic significance.

Results

Analyses of data from all patients (n = 99) resulted in parameter sets that allowed direct prediction of the NSLN status with a ROC area under the curve (AUC) of 0.83. The clinically most relevant prediction of NSLN status in SLN-positive patients (n = 37) based on only seven parameters (including TIMP-2 as the most relevant single value) was possible with high accuracy indicated by an AUC of 0.89.

Conclusions

Parallel assessment of protein concentrations in breast biopsies is a highly promising approach to predict nodal involvement and even the NSLN status in SLN-negative breast cancer patients. Such diagnostic information could substantially reduce the number of completion axillary lymph node dissections in clinical practice.
Literature
go back to reference Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119. doi:10.1007/s10549-004-5781-z PubMedCrossRef Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119. doi:10.​1007/​s10549-004-5781-z PubMedCrossRef
go back to reference Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27:2946–2953. doi:10.1200/JCO.2008.19.5750 PubMedCrossRef Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27:2946–2953. doi:10.​1200/​JCO.​2008.​19.​5750 PubMedCrossRef
go back to reference Cao Y (2005) Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle 4:228–230PubMedCrossRef Cao Y (2005) Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle 4:228–230PubMedCrossRef
go back to reference Erb KM, Julian TB (2009) Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep 11:15–20PubMedCrossRef Erb KM, Julian TB (2009) Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep 11:15–20PubMedCrossRef
go back to reference Giuliano AE, Jones RC, Brennan M, Statman R (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345–2350PubMed Giuliano AE, Jones RC, Brennan M, Statman R (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345–2350PubMed
go back to reference Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 305:569–575. doi:10.1001/jama.2011.90 PubMedCrossRef Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 305:569–575. doi:10.​1001/​jama.​2011.​90 PubMedCrossRef
go back to reference Gur AS, Unal B, Ozbek U, Ozmen V, Aydogan F, Gokgoz S, Gulluoglu BM, Aksaz E, Ozbas S, Baskan S, Koyuncu A, Soran A (2010) Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol 36:30–35. doi:10.1016/j.ejso.2009.05.007 PubMed Gur AS, Unal B, Ozbek U, Ozmen V, Aydogan F, Gokgoz S, Gulluoglu BM, Aksaz E, Ozbas S, Baskan S, Koyuncu A, Soran A (2010) Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol 36:30–35. doi:10.​1016/​j.​ejso.​2009.​05.​007 PubMed
go back to reference Houvenaeghel G, Nos C, Giard S, Mignotte H, Esterni B, Jacquemier J, Buttarelli M, Classe JM, Cohen M, Rouanet P, Penault LF, Bonnier P, Marchal F, Garbay JR, Fraisse J, Martel P, Fondrinier E, Tunon dL, Rodier JF (2009) A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 35:690–695. doi:10.1016/j.ejso.2008.10.003 PubMed Houvenaeghel G, Nos C, Giard S, Mignotte H, Esterni B, Jacquemier J, Buttarelli M, Classe JM, Cohen M, Rouanet P, Penault LF, Bonnier P, Marchal F, Garbay JR, Fraisse J, Martel P, Fondrinier E, Tunon dL, Rodier JF (2009) A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 35:690–695. doi:10.​1016/​j.​ejso.​2008.​10.​003 PubMed
go back to reference Katz A, Niemierko A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP, Petrucci PE, Flax R, Drogula C, Magnant C (2006) Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol 93:550–558. doi:10.1002/jso.20514 PubMedCrossRef Katz A, Niemierko A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP, Petrucci PE, Flax R, Drogula C, Magnant C (2006) Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol 93:550–558. doi:10.​1002/​jso.​20514 PubMedCrossRef
go back to reference Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE (2010) Erratum to: axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol 17:552–557. doi:10.1245/s10434-009-0800-2 PubMedCrossRef Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE (2010) Erratum to: axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol 17:552–557. doi:10.​1245/​s10434-009-0800-2 PubMedCrossRef
go back to reference Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66. doi:10.1186/1471-2407-8-66 PubMedCrossRef Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66. doi:10.​1186/​1471-2407-8-66 PubMedCrossRef
go back to reference Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M (2009) Axillary lymph node dissection for sentinel lymph node micrometastasis may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 16:3366–3374. doi:10.1586/14737140.8.2.195 PubMedCrossRef Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M (2009) Axillary lymph node dissection for sentinel lymph node micrometastasis may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 16:3366–3374. doi:10.​1586/​14737140.​8.​2.​195 PubMedCrossRef
go back to reference Murphy AN, Unsworth EJ, Stetler-Stevenson WG (1993) Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157:351–358PubMedCrossRef Murphy AN, Unsworth EJ, Stetler-Stevenson WG (1993) Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157:351–358PubMedCrossRef
go back to reference Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E, Cao Y (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117:2766–2777. doi:10.1172/JCI32479 PubMedCrossRef Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E, Cao Y (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117:2766–2777. doi:10.​1172/​JCI32479 PubMedCrossRef
go back to reference Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309. doi:10.1002/bjs.5943 PubMedCrossRef Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309. doi:10.​1002/​bjs.​5943 PubMedCrossRef
go back to reference Perhavec A, Perme MP, Hocevar M, Besic N, Zgajnar J (2010) Ljubljana nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node. Breast Cancer Res Treat 119:357–366. doi:10.1007/s10549-009-0561-4 PubMedCrossRef Perhavec A, Perme MP, Hocevar M, Besic N, Zgajnar J (2010) Ljubljana nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node. Breast Cancer Res Treat 119:357–366. doi:10.​1007/​s10549-009-0561-4 PubMedCrossRef
go back to reference Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H (2008) Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 14:3345–3353. doi:10.1158/1078-0432.CCR-07-4802 PubMedCrossRef Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H (2008) Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 14:3345–3353. doi:10.​1158/​1078-0432.​CCR-07-4802 PubMedCrossRef
go back to reference Turner RR, Ollila DW, Krasne DL, Giuliano AE (1997) Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226:271–276PubMedCrossRef Turner RR, Ollila DW, Krasne DL, Giuliano AE (1997) Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226:271–276PubMedCrossRef
go back to reference van Deurzen CH, de Boer M, Monninkhof EM, Bult P, van der WE, Tjan-Heijnen VC, van Diest PJ (2008) Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 100:1574–1580. doi:10.1093/jnci/djn343 PubMedCrossRef van Deurzen CH, de Boer M, Monninkhof EM, Bult P, van der WE, Tjan-Heijnen VC, van Diest PJ (2008) Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 100:1574–1580. doi:10.​1093/​jnci/​djn343 PubMedCrossRef
go back to reference Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS III, Kattan MW (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS III, Kattan MW (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef
go back to reference Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903–911. doi:10.1038/sj.bjc.6605569 PubMedCrossRef Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903–911. doi:10.​1038/​sj.​bjc.​6605569 PubMedCrossRef
go back to reference Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X (2008) Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 8:83. doi:10.1186/1471-2407-8-83 PubMedCrossRef Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X (2008) Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 8:83. doi:10.​1186/​1471-2407-8-83 PubMedCrossRef
Metadata
Title
Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays
Authors
Georg Sauer
Nicole Schneiderhan-Marra
Rainer Muche
Karin Koretz
Cornelia Kazmaier
Rolf Kreienberg
Thomas Joos
Helmut Deissler
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-0982-4

Other articles of this Issue 8/2011

Journal of Cancer Research and Clinical Oncology 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.